DocDollars

Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.)

NJ · United States · Reporting entity ID 100000781818

Total reported 2019–2025
$228.6M
#53 of 2,960 reporting companies — 0.3% of all reported industry payments
$50.3M in general payments across 622,172 records, plus $178.3M in research funding across 33,986 records.

How it breaks down

General payments $50,268,470
Research funding $178,307,093

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) reported $228.6M to US doctors and teaching hospitals from 2019 to 2025, ranking #53 of 2,960 reporting companies. 78% of that was research funding and 22% general payments such as consulting, speaking, food and travel. 622,172 general payment records and 33,986 research records were filed.

Common questions about Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.)

How much has Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) paid US doctors?

Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) reported $228,575,564 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $50,268,470 in general payments, $178,307,093 in research funding.

How does Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) rank among drug and device companies?

It ranks #53 of 2,960 reporting entities by total reported value, about 0.3% of all industry payments in the dataset.

Does a payment from Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.